Eli Lilly Lifts Revenue Outlook on Weight-Loss Drug Sales, Trims Profit View on Deal Charges
The drugmaker lifted its revenue outlook to $91 billion to $92 billion as Zepbound and Mounjaro sales beat estimates, while deal charges cut profit guidance.
- On Thursday, Eli Lilly raised its full-year revenue forecast to $91 billion–$92 billion and beat third-quarter earnings, propelled by surging demand for injectable weight-loss drugs and reaching a $1.2 trillion market valuation.
- Sales of the diabetes drug Mounjaro reached $10.72 billion, topping expectations, while obesity injection Zepbound generated $5.35 billion; Foundayo revenue trailed at $184 million.
- Market data from Bernstein shows Lilly captured about 70% of the 700,000 Medicare patients who recently initiated GLP-1 treatment, demonstrating strong market penetration.
- Despite strong revenue gains, Lilly trimmed its adjusted profit outlook to $35.00–$36.00 per share, as $4.57 per share in research charges from acquisitions of AtaiBeckley and Curevo offset underlying improvements.
- Wall Street is shifting attention toward retatrutide, Lilly's next-generation weight-loss candidate slated for regulatory submission next year, which showed 24% average weight loss in midstage trials.
23 Articles
23 Articles
Eli Lilly lifts revenue outlook on weight-loss drug sales
Eli Lilly has raised its full-year revenue forecast and beat third-quarter earnings expectations, propelled by surging demand for injectable weight-loss drugs that could allay investor concerns about price erosion in US government health plans.
Eli Lilly totaled approximately $6.45 billion in net profit in the third quarter of 2026, 16% higher than in the same period of the previous year. The company based in Indianapolis, United States, released the quarterly balance sheet on Thursday morning (29). Between July and September, pharmaceutical revenue increased 39% in the annual comparison to $24.4 billion, driven by sales of Mounjaro and Zepbound medicines. According to Eli Lilly, the g…
The United States Eli Lilly, the world's largest capitalization pharmaceutical company, increased net profits and revenues in the third quarter of 2026, and significantly improved the revenue forecast for the current year.
BT
avisendanmark.dkNovo competitor Eli Lilly surprises positively with financial figures from the third quarter.
Coverage Details
Bias Distribution
- 46% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
